Corcept Therapeutics Incorporated Insider Trading

CORT

Last 12 months

Insiders bought $3.31M and sold $100M on the open market.

93% of the selling was scheduled in advance under 10b5-1 plans. Director Kimberly Park sold $3.27M on Aug 26, 100% of their stake, outside a plan.

Net open-market

−$96.7M

1 buy · 50 sales

Under a 10b5-1 plan

93%

of the value sold

Insiders who bought / sold

1 / 10

executives and directors

Last open-market buy

Mar 2026

Mar 17, 2026

Get an email when CORT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 2 – 3	Sean Maduck Other	Sold10b5-1 plan 3 parts	25,000	$81.85 average	$2.05M	45%	Form 4
Nov 2	Roberto Wandenkolk Vieira President, Oncology	Sold10b5-1 plan 2 parts	8,333	$80.89 average	674K	68%	Form 4
Oct 15	James N Wilson Director	Sold10b5-1 plan 3 parts	10,000	$114.81 average	$1.15M	0.7%	Form 4
Oct 2	Roberto Wandenkolk Vieira President, Oncology	Sold10b5-1 plan 3 parts	8,333	$116.10 average	967K	68%	Form 4
Oct 1 – 2	Joseph Douglas Lyon See Remarks	Sold10b5-1 plan 3 parts	10,000	$116.07 average	$1.16M	64%	Form 4
Oct 1 – 2	Sean Maduck See Remarks	Sold10b5-1 plan 3 parts	25,000	$116.26 average	$2.91M	62%	Form 4
Sep 16	Roberto Wandenkolk Vieira President, Oncology	Sold10b5-1 plan	296	$100.82	30K	7.0%	Form 4
Sep 15	James N Wilson Director	Sold10b5-1 plan 3 parts	10,000	$110.69 average	$1.11M	0.7%	Form 4
Sep 14	Joseph Douglas Lyon See Remarks	Sold10b5-1 plan 2 parts	10,000	$113.50 average	$1.13M	64%	Form 4
Sep 2	Roberto Wandenkolk Vieira President, Oncology	Sold10b5-1 plan 7 parts	58,333	$110.76 average	$6.46M	93%	Form 4
Sep 1	Sean Maduck See Remarks	Sold10b5-1 plan 3 parts	25,000	$114.43 average	$2.86M	56%	Form 4
Aug 26	Kimberly Park Director	SoldNo plan	26,685	$122.55	$3.27M	100%	Form 4
Aug 25	Sean Maduck See Remarks	Sold10b5-1 plan 2 parts	30,955	$125.58 average	$3.89M	61%	Form 4
Aug 18	David L Mahoney Director	Sold10b5-1 plan 4 parts	103,606	$118.25 average	$12.3M	8.2%	Form 4
Aug 17	Gary Charles Robb Chief Business Officer	SoldNo plan	10,000	$116.26	$1.16M	13%	Form 4
Aug 14	Sean Maduck See Remarks	Sold10b5-1 plan	3,664	$114.49	419K	7.7%	Form 4
Aug 14	James N Wilson Director	Sold10b5-1 plan 3 parts	10,000	$111.42 average	$1.11M	0.7%	Form 4
Aug 10	Sean Maduck See Remarks	Sold10b5-1 plan	1,031	$114.52	118K	2.3%	Form 4
Aug 10	William Guyer Chief Development Officer	Sold10b5-1 plan 2 parts	16,300	$113.43 average	$1.85M	80%	Form 4
Aug 4	William Guyer Chief Development Officer	Sold10b5-1 plan	3,700	$113.12	419K	48%	Form 4
Aug 3	Sean Maduck See Remarks	Sold10b5-1 plan	20,305	$114.70	$2.33M	58%	Form 4
Aug 3	Joseph Douglas Lyon See Remarks	SoldNo plan	1,540	$114.16	176K	22%	Form 4
Jul 30	Atabak Mokari Chief Financial Officer	Sold10b5-1 plan 13 parts	80,000	$114.72 average	$9.18M	83%	Form 4
Jul 15	James N Wilson Director	Sold10b5-1 plan 4 parts	10,000	$88.30 average	883K	0.7%	Form 4
Jul 15	Atabak Mokari Chief Financial Officer	Sold10b5-1 plan 4 parts	40,000	$87.71 average	$3.51M	71%	Form 4
Jul 7	William Guyer Chief Development Officer	Sold10b5-1 plan 2 parts	20,000	$93.13 average	$1.86M	83%	Form 4
Jul 1	Sean Maduck See Remarks	Sold10b5-1 plan 3 parts	25,000	$88.35 average	$2.21M	63%	Form 4
Jun 17	David L Mahoney Director	SoldNo plan	20,000	$84.53	$1.69M	1.6%	Form 4
Jun 16	James N Wilson Director	Sold10b5-1 plan 2 parts	10,000	$83.20 average	832K	0.7%	Form 4
Jun 15	Atabak Mokari Chief Financial Officer	Sold10b5-1 plan 4 parts	40,000	$81.15 average	$3.25M	71%	Form 4
Jun 2	William Guyer Chief Development Officer	Sold10b5-1 plan	20,000	$70.60	$1.41M	83%	Form 4
Jun 1	Sean Maduck See Remarks	Sold10b5-1 plan 2 parts	25,000	$70.21 average	$1.76M	56%	Form 4
Jun 1	Atabak Mokari Chief Financial Officer	Sold10b5-1 plan	40,000	$70.00	$2.8M	71%	Form 4
Jun 1	Joseph K Belanoff Chief Executive Officer	Sold10b5-1 plan	12,837	$69.74	895K	0.4%	Form 4
May 27	Joseph Douglas Lyon See Remarks	SoldNo plan	5,000	$65.00	325K	45%	Form 4
May 27	Sean Maduck See Remarks	Sold10b5-1 plan 2 parts	75,000	$65.59 average	$4.92M	64%	Form 4
May 5	William Guyer Chief Development Officer	Sold10b5-1 plan	20,000	$51.83	$1.04M	90%	Form 4
May 1	Joseph K Belanoff Chief Executive Officer	Sold10b5-1 plan	40,000	$50.10	$2M	1.4%	Form 4
Apr 7	William Guyer Chief Development Officer	Sold10b5-1 plan	20,000	$40.97	819K	90%	Form 4
Mar 25	Joseph K Belanoff Chief Executive Officer	Sold10b5-1 plan	26,198	$50.07	$1.31M	0.9%	Form 4

Nov 2 – 310b5-1 plan
Sean Maduck
Other · sold 25,000 at avg $81.85
$2.05M
45% of stake
Nov 210b5-1 plan
Roberto Wandenkolk Vieira
President, Oncology · sold 8,333 at avg $80.89
674K
68% of stake
Oct 1510b5-1 plan
James N Wilson
Director · sold 10,000 at avg $114.81
$1.15M
0.7% of stake
Oct 210b5-1 plan
Roberto Wandenkolk Vieira
President, Oncology · sold 8,333 at avg $116.10
967K
68% of stake
Oct 1 – 210b5-1 plan
Joseph Douglas Lyon
See Remarks · sold 10,000 at avg $116.07
$1.16M
64% of stake
Oct 1 – 210b5-1 plan
Sean Maduck
See Remarks · sold 25,000 at avg $116.26
$2.91M
62% of stake
Sep 1610b5-1 plan
Roberto Wandenkolk Vieira
President, Oncology · sold 296 at $100.82
30K
7.0% of stake
Sep 1510b5-1 plan
James N Wilson
Director · sold 10,000 at avg $110.69
$1.11M
0.7% of stake
Sep 1410b5-1 plan
Joseph Douglas Lyon
See Remarks · sold 10,000 at avg $113.50
$1.13M
64% of stake
Sep 210b5-1 plan
Roberto Wandenkolk Vieira
President, Oncology · sold 58,333 at avg $110.76
$6.46M
93% of stake
Sep 110b5-1 plan
Sean Maduck
See Remarks · sold 25,000 at avg $114.43
$2.86M
56% of stake
Aug 26No plan
Kimberly Park
Director · sold 26,685 at $122.55
$3.27M
100% of stake
Aug 2510b5-1 plan
Sean Maduck
See Remarks · sold 30,955 at avg $125.58
$3.89M
61% of stake
Aug 1810b5-1 plan
David L Mahoney
Director · sold 103,606 at avg $118.25
$12.3M
8.2% of stake
Aug 17No plan
Gary Charles Robb
Chief Business Officer · sold 10,000 at $116.26
$1.16M
13% of stake
Aug 1410b5-1 plan
Sean Maduck
See Remarks · sold 3,664 at $114.49
419K
7.7% of stake
Aug 1410b5-1 plan
James N Wilson
Director · sold 10,000 at avg $111.42
$1.11M
0.7% of stake
Aug 1010b5-1 plan
Sean Maduck
See Remarks · sold 1,031 at $114.52
118K
2.3% of stake
Aug 1010b5-1 plan
William Guyer
Chief Development Officer · sold 16,300 at avg $113.43
$1.85M
80% of stake
Aug 410b5-1 plan
William Guyer
Chief Development Officer · sold 3,700 at $113.12
419K
48% of stake
Aug 310b5-1 plan
Sean Maduck
See Remarks · sold 20,305 at $114.70
$2.33M
58% of stake
Aug 3No plan
Joseph Douglas Lyon
See Remarks · sold 1,540 at $114.16
176K
22% of stake
Jul 3010b5-1 plan
Atabak Mokari
Chief Financial Officer · sold 80,000 at avg $114.72
$9.18M
83% of stake
Jul 1510b5-1 plan
James N Wilson
Director · sold 10,000 at avg $88.30
883K
0.7% of stake
Jul 1510b5-1 plan
Atabak Mokari
Chief Financial Officer · sold 40,000 at avg $87.71
$3.51M
71% of stake
Jul 710b5-1 plan
William Guyer
Chief Development Officer · sold 20,000 at avg $93.13
$1.86M
83% of stake
Jul 110b5-1 plan
Sean Maduck
See Remarks · sold 25,000 at avg $88.35
$2.21M
63% of stake
Jun 17No plan
David L Mahoney
Director · sold 20,000 at $84.53
$1.69M
1.6% of stake
Jun 1610b5-1 plan
James N Wilson
Director · sold 10,000 at avg $83.20
832K
0.7% of stake
Jun 1510b5-1 plan
Atabak Mokari
Chief Financial Officer · sold 40,000 at avg $81.15
$3.25M
71% of stake
Jun 210b5-1 plan
William Guyer
Chief Development Officer · sold 20,000 at $70.60
$1.41M
83% of stake
Jun 110b5-1 plan
Sean Maduck
See Remarks · sold 25,000 at avg $70.21
$1.76M
56% of stake
Jun 110b5-1 plan
Atabak Mokari
Chief Financial Officer · sold 40,000 at $70.00
$2.8M
71% of stake
Jun 110b5-1 plan
Joseph K Belanoff
Chief Executive Officer · sold 12,837 at $69.74
895K
0.4% of stake
May 27No plan
Joseph Douglas Lyon
See Remarks · sold 5,000 at $65.00
325K
45% of stake
May 2710b5-1 plan
Sean Maduck
See Remarks · sold 75,000 at avg $65.59
$4.92M
64% of stake
May 510b5-1 plan
William Guyer
Chief Development Officer · sold 20,000 at $51.83
$1.04M
90% of stake
May 110b5-1 plan
Joseph K Belanoff
Chief Executive Officer · sold 40,000 at $50.10
$2M
1.4% of stake
Apr 710b5-1 plan
William Guyer
Chief Development Officer · sold 20,000 at $40.97
819K
90% of stake
Mar 2510b5-1 plan
Joseph K Belanoff
Chief Executive Officer · sold 26,198 at $50.07
$1.31M
0.9% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CORT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with CORT

CompareIntrinsic value

HRMYHarmony Biosciences Holdings, Inc.

$34.42-7.04%82

ANIPAni Pharmaceuticals Inc.

$72.89+0.84%85

KNSAKiniksa Pharmaceuticals International, plc

$96.12+3.03%71

BBIOBridgeBio Pharma, Inc.

$77.89+5.21%30

IONSIonis Pharmaceuticals, Inc.

$40.15-0.67%39

AXSMAxsome Therapeutics, Inc.

$137.00-1.87%10

SUPNSupernus Pharmaceuticals Inc.

$28.21+0.21%44

PBHPrestige Consumer Healthcare Inc.

$53.28+7.55%48

Held by ETFs

CORT is in 108 US ETFs. The largest of them, with CORT's weight in each:

Spot a number that looks wrong? Check it in CORT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CORT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.